Blue Light Therapy Market is Segmented By Product Type (Light Box, Floor & Desk Lamps, Light Visor, Handheld Devices for Skin Treatment (HDST), Blue Light Therapy Bulbs, Others), By Application (Psoriasis, Vitiligo, Eczema, Acne Vulgaris, Sleeping Disorders, Seasonal Affective Disorders (SAD), Others), By End-User (Hospitals, Clinics, Homecare Settings, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Blue light therapy market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 5% during the forecast period (2023-2030). The most common uses of blue light therapy are to treat sun damage and premalignant or malignant skin cancer growths. It can prevent skin cancer and remove precancerous and cancerous skin lesions that haven't spread to other parts of the body (or metastasized).
Blue Light Therapy Market
| Metrics | Details |
| Market CAGR | 5% |
| Segments Covered | By Product Type, By Application, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Market Dynamics
The factors influencing the global blue light therapy market are the increasing applications of blue light therapy and the increasing prevalence of seasonal affective disorder (SAD).
The increasing application of blue light therapy is expected to drive the market growth in the forecast period
The most common uses of blue light therapy are to treat sun damage and premalignant or malignant skin cancer growths. It can be used to prevent skin cancer and remove precancerous and cancerous skin lesions that haven't spread to other parts of the body (or metastasized). Other types of skin disorders can also be treated with blue light therapy. It can be used to reduce sebaceous hyperplasia or enlarged oil glands and improve skin texture. It can help remove sunspots, acne scars, and even scars caused by acne.
Some blue light treatments, a type of phototherapy, have been approved by the Food and Drug Administration (FDA) for moderate acne vulgaris that hasn't responded to other treatments. There is evidence that blue light therapy can help treat or prevent acne outbreaks. However, research has yet to confirm that it is as effective as or more effective than topical retinoids and other treatments. Blue light appears to be safe, with only minor side effects. According to the American Academy of Dermatology, it is free of UV rays, and there is no evidence that it increases the risk of skin cancer or aging (AAD). Blue light therapy can be done in a dermatologist's office or home. It can be used to treat depression and skin conditions, and cancer. It's particularly useful for treating the major depressive disorder with seasonal patterns, also known as seasonal affective disorder (SAD). The gloomy winter weather, shorter days, and more time spent indoors are all factors that contribute to this condition. It is possible to treat it with light.
The side effects associated with blue light therapy are expected to hamper the market growth
The increasing side effects associated with blue light therapy are expected to hamper the market growth. For instance, the area may be red, swollen, tender, and mildly bruised or blistered immediately after treatment, especially if medication has been applied to the skin. It's normal for the treated area to crust over or peel. The majority of people recover in 7 days, and the crusting disappears in 3 to 14 days.
If light-sensitive drugs are used for photodynamic therapy, as they usually are, the skin will be extremely sensitive to light for several weeks afterward. Bright, direct sunlight should be avoided, though fluorescent lights are acceptable. Sunscreens will not work because they only protect against UV light, not photosensitive reactions. Blue light therapy treatment has no significant long-term side effects when used properly. It's much less invasive than surgery, and the treated area usually heals with little or no scarring. Moreover, without the addition of photosensitivity drugs, blue light therapy is safe and poses few risks. The most serious risk is a skin infection if any post-treatment blisters develop and are popped or neglected. Patients with a rare blood disorder called porphyria, which causes increased light sensitivity, or has allergies to porphyrins, shouldn't use blue light therapy.
COVID-19 Impact Analysis
The BLU developed by the researchers can deliver safe wavelengths of visible blue light at selectable densities to inactivate SARS-CoV-2, regardless of whether it is inside or outside of a cell. The BLUs have narrow emission profiles and optimised LED arrays. These arrays can reliably and consistently illuminate assay plates with specific light doses. The spectral flux relative to the wavelength characterizes each LED array. They discovered that 405nm LEDs emit 16.5 percent of their flux in the UVA spectrum, while 425nm light wavelengths are nearly completely visible. The further research on the use of blue light therapy for use in covid-19 is expected to have a positive impact on the market growth in the forecast period.
Segment Analysis
Based on application, the psoriasis segment is expected to dominate the market growth
Psoriasis is a skin condition that causes red, itchy, scaly patches on the knees, elbows, trunk, and scalp, among other places. Psoriasis is a chronic (long-term) disease that has no cure. It goes through cycles, with flare-ups lasting a few weeks or months, then subsiding or going into remission. According to the World Psoriasis Day consortium, 125 million people worldwide 2 to 3% of the total population, have psoriasis.
The US Food and Drug Administration (FDA) approved a wearable blue-light device that can be used at home to treat mild psoriasis. It provides a gentle, user-friendly treatment. One should simply strap it to their arm or leg, depending on where psoriasis is mild. Moreover, many companies are manufacturing devices that are expected to boost this segment's growth. For instance, Philips' BlueControl wearable device emits UV-free blue LED light that induces natural, drug-free processes in the skin to significantly reduce symptoms of mild psoriasis vulgaris, the most common form of psoriasis, such as redness, scaling, and plaque thickness.
Geographical Analysis
North America region is expected to hold the largest market share in the global blue light therapy market
The rising prevalence of seasonal affective disorder (SAD) and growing technological developments in this region is expected to drive the market growth. For treating SAD, a type of depression linked to seasonal changes, narrow-band blue light is as effective as bright white light. According to the American Psychiatric Association, approximately 5.0 percent of adults in the United States suffer from this disorder each year, lasting for nearly 40%. Women are more likely than men to be affected by SAD, and younger people are more likely to be affected than older people. A family history of SAD or depressive disorder and bipolar disorder are all risk factors for SAD and the ones listed above.
Competitive Landscape
With mergers, collaborations, and product launches, the global blue light therapy market is moderately competitive. Some of the key players in the market are Philps Koninklijke NV, North Light Technologies, Veriflux Inc., Nature Bright, Zepter International, PhotoMedex, Axion Ltd, Kernel Medical Equipment Co., LTD, and Beurer
Philps Koninklijke NV
Overview: The health technology company Nature Bright is based in the Netherlands. Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other, and Legacy Items are the company's segments. The company is based in Amsterdam, Netherlands, founded in 1891.
Product Portfolio: Philips' BlueControl wearable device emits UV-free blue LED light that induces natural, drug-free processes in the skin to reduce symptoms of mild psoriasis vulgaris significantly, the most common form of psoriasis, such as redness, scaling, and plaque thickness.
